Dendrimers and dendritic polymers in drug delivery

Drug Discovery Today

Volumn 10, Issue 1, 2005, Pages 35-43

  Gillies, Elizabeth R ^a   Fréchet, Jean M J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biochemistry; Biocompatible; Boron neutron capture therapy; Cancer; Cancer biology; Dendrimer drug conjugates; Drug Discovery; Pharmaceutical Science; Photodynamic therapy

Indexed keywords

CISPLATIN; DENDRIMER; DOXORUBICIN;

BIOCOMPATIBILITY; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENCAPSULATION; MOLECULAR WEIGHT; NEUTRON CAPTURE THERAPY; PHOTODYNAMIC THERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; BORON NEUTRON CAPTURE THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; POLYMERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12844258906     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03276-3     Document Type: Review

References (80)

1. Fréchet J.M.J., Tomalia D. Dendrimers and Other Dendritic Polymers. 2001;John Wiley & Sons
2. Newkome G.R., et al. Dendrimers and Dendrons: Concepts, Syntheses, Applications. 2001;Wiley-VCH
3. Tomalia D.A., et al. A new class of polymers: starburst-dendritic macromolecules. Polym. J. 17:1985;117-132
4. Newkome G.R., et al. Cascade molecules: a new approach to micelles. A [27]-Arborol. J. Org. Chem. 50:1985;2003-2004
5. Aulenta F., et al. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur. Polym. J. 39:2003;1741-1771
6. Stiriba S-E., et al. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew. Chem. Int. Ed. Engl. 41:2002;1329-1334
7. Patri A.K., et al. Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6:(466):2002;471
8. Boas U., Heegaard P.M.H. Dendrimers in drug research. Chem. Soc. Rev. 33:2004;43-63
9. Wang Y-S., et al. Structural and biological characterization of pegylated recombinant interferon-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54:2002;547-570
10. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 10:2004;1235-1244
11. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2:2003;347-360
12. Esfand R., Tomalia D.A. Polyamidoamine (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today. 6:2001;427-436
13. 125I-labeled polyamidoamine dendrimers in vivo. J. Control. Release. 65:2000;133-148
14. Jevpraesesphant R., et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252:2003;263-266
15. Hawker C.J., Fréchet J.M.J. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J. Am. Chem. Soc. 112:1990;7638-7647
16. Liu M., et al. Water-soluble unimolecular micelles: their potential as drug delivery agents. J. Control. Release. 65:2000;121-131
17. Liu M., et al. Water-soluble dendrimer-polyethylene glycol starlike conjugates as potential drug carriers. J. Polym. Sci. A. 37:1999;3492-3503
18. Denkewalter R.G., et al. Macromolecular highly branched -diaminocarboxylic acids. Chem. Abstr. 100:1984
19. Sadler K., Tam J.P. Peptide dendrimers: applications and synthesis. J. Biotechnol. 90:2002;195-229
20. Roy R., Baek M-G. Glycodendrimers: novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein. J. Biotechnol. 90:2002;291-309
21. Bezouška K. Design, functional evaluation and biomedical applications of carbohydrate dendrimers (glycodendrimers). J. Biotechnol. 90:2002;269-290
22. Grayson S.M., et al. Convergent synthesis and 'surface' functionalization of a dendritic analog of polyethylene glycol. Chem. Commun. 1999;1329-1330
23. Ihre H., et al. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug. Chem. 13:2002;433-452
24. Padilla De Jesús O.L., et al. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem. 13:2002;453-461
25. Grinstaff M.W. Biodendrimers: new polymeric biomaterials for tissue engineering. Chemistry. 8:2002;2839-2846
26. Boysen M.M.K., et al. Glycerol and glycerol glycol glycodendrimers. Eur. J. Org. Chem. 2003;4376-4386
27. Frey H., Haag R. Dendritic polyglycerol: a new versatile biocompatible material. J. Biotechnol. 90:2002;257-267
28. Haag R., et al. An approach to glycerol dendrimers and pseudo-dendritic polyglycerols. J. Am. Chem. Soc. 122:2000;2954-2955
29. Fuchs S., et al. A set of surface-modified dendrimers with potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization. Chem. Eur. J. 10:2004;1167-1192
30. Neerman M.F., et al. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int. J. Pharm. 281:2004;129-132
31. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3:1992;175-210
32. Maeda H., Matsumura Y. A new concept in macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46:1986;6387-9392
33. Haensler J., Szoka F.C. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 4:1993;372-379
34. Jansen J.F.G.A., et al. Encapsulation of guest molecules into a dendritic box. Science. 266:1994;1226-1229
35. Jansen J.F.G.A., et al. The dendritic box: shape-selective liberation of encapsulated guests. J. Am. Chem. Soc. 117:1995;4417-4418
36. Newkome G.R., et al. Chemistry of micelles. 13. Unimolecular micelles. Angew. Chem. Int. Ed. Engl. 30:1991;1178-1180
37. Hawker C.J., et al. Unimolecular micelles and globular amphiphiles: dendritic macromolecules as novel recyclable solubilization agents. J. Chem. Soc. 1:1993;1287-1297
38. Kojima C., et al. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11:2000;910-917
39. Bhadra D., et al. A PEGylated dendritic nanoparticle carrier of fluorouracil. Int. J. Pharm. 257:2003;111-124
40. Gillies E.R., et al. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J. Am. Chem. Soc. 126:2004;11936-11943
41. Malik N., et al. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 10:1999;767-776
42. Duncan R., Malik N. Dendrimers: biocompatibility and potential for delivery of anticancer agents. Proc. Int. Symp. Control. Release Bioact. Mater. 23:1996;105-106
43. Zhou R.X., et al. In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J. Control. Release. 57:1999;249-257
44. 4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control. Release. 79:2002;55-70
45. Schiavon O., et al. PEG-Ara-C conjugates for controlled release. Eur. J. Med. Chem. 39:2004;123-133
46. Wang D., et al. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers. Biomacromolecules. 1:2000;313-319
47. Kono K., et al. Design of dendritic macromolecules containing folate or methotrexate residues. Bioconjug. Chem. 10:1999;1115-1121
48. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41:2000;147-162
49. Quintana A., et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19:2002;1310-1316
50. Nishikawa M., et al. Pharmacokinetic evaluation of polymeric carriers. Adv. Drug Deliv. Rev. 21:1996;135-155
51. Pang S.N.J. Final report on the safety assessment of polyethylene glycols (PEGs)-6, -8, -32, -150, -14M, -20M. J. Am. Coll. Toxicol. 12:1993;429-457
52. Greenfield R.S., et al. In vitro evaluation of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linke. Cancer Res. 50:1990;6600-6607
53. Gillies E.R., Fréchet J.M.J. Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) 'bow-tie' hybrids with tunable molecular weight and architecture. J. Am. Chem. Soc. 124:2002;14137-14146
54. Grayson S.M., Fréchet J.M.J. Divergent synthesis of dendronized poly(p-hydroxystyrene. Macromolecules. 34:2001;6542-6544
55. Lee C.C., et al. Synthesis of narrow-polydispersity degradable dendronized aliphatic polyesters. J. Polym. Sci. A. 42:2004;3563-3578
56. Barth R.F., et al. Boron neutron capture therapy for cancer. Realities and prospects. Cancer. 70:1992;2995-3007
57. Hawthorne M.F. The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem. Int. Ed. Engl. 32:1993;950-984
58. Barth R.F., et al. Delivery of Boron-10 for Neutron Capture Therapy by Means of Polyclonal and Monoclonal Antibodie. Progress and Problems. 1986;Nishimura Co. Ltd.
59. Alam F., et al. Dicesium N-succinimidyl 3-(undecahydro-closo- dodecaboranyldithio)propionate, a novel heterobifunctional boronating agen. J. Med. Chem. 28:1985;522-525
60. Barth R.F., et al. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug. Chem. 5:1994;58-66
61. Sauter G., et al. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol. 148:1996;1047-1053
62. Capala J., et al. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug. Chem. 7:1996;7-15
63. Yang W., et al. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res. 57:1997;4333-4339
64. Wu G., et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug. Chem. 15:2004;185-194
65. Huang S.M., et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940
66. Skukla S., et al. Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug. Chem. 14:2003;158-167
67. Qualmann B., et al. Synthesis of boron-rich lysine dendrimers as protein labels in electron microscopy. Angew. Chem. Int. Ed. Engl. 35:1996;909-911
68. Nemoto H., et al. Synthesis of a water-soluble o-carbaborane bearing a uracil moiety via a palladium-catalyzed reaction under essentially neutral conditions. Chem. Commun. 1994;577-578
69. Newkome G.R., et al. Chemistry within a unimolecular micelle precursor: boron superclusters by site- and depth-specific transformations of dendrimers. Angew. Chem. Int. Ed. Engl. 33:1994;666-668
70. Dougherty T.J., et al. Photodynamic therapy. J. Natl. Cancer Inst. 90:1998;889-905
71. Peng Q., et al. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem. Photobiol. 65:1997;235-251
72. Battah S.H., et al. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjug. Chem. 12:2001;980-988
73. Nishiyama N., et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjug. Chem. 14:2003;58-66
74. Zhang G-D., et al. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J. Control. Release. 93:2003;141-150
75. Brasseur N., et al. Water-soluble aluminum phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumor-bearing mice. Br. J. Cancer. 80:1999;1533-1541
76. Oh D.H., et al. Two-photon excitation of 4-hydroxymethyl-4,5,8- trimethylpsoralen. Photochem. Photobiol. 65:1997;91-95
77. Dichtel W.R., et al. Singlet oxygen generation via two-photon excited FRET. J. Am. Chem. Soc. 126:2004;5380-5381
78. Amir R.J., et al. Self-immolative dendrimers. Angew. Chem. Int. Ed. Engl. 42:2003;4494-4499
79. de Groot F.M.H., et al. 'Cascade-release dendrimers' liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem. Int. Ed. Engl. 42:2003;4490-4494
80. Shamis M., et al. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc. 126:2004;1726-1731